Meng Mao

Dr. Meng Mao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Aging
Verified
Journal Article
Open access
PDF file
YWYangyang Wu
Yangyang Wu
MMMeng Mao
Meng Mao
LWLin-jian Wang
Lin-jian Wang
Background: Glioma is the most frequent primary tumor of the central nervous system. The high heterogeneity of glioma tumors enables them to adapt to challenging environments, leading to resistance to treatment. Therefore, to detect the driving factors and improve the prognosis of glioma, it is essential to have a comprehensive understanding of the genomic heterogeneity, stemness, and immune microenvironment of glioma. Methods: We classified gliomas into various subtypes based on stemness, genomic heterogeneity, and immune microenvironment consensus clustering analysis. We identified risk hub genes linked to heterogeneous characteristics using WGCNA, LASSO, and multivariate Cox regression analysis and utilized them to create an effective risk model. Results: We thoroughly investigated the genomic heterogeneity, stemness, and immune microenvironment of glioma and identified the risk hub genes RAB42, SH2D4A, and GDF15 based on the TCGA dataset. We developed a risk model utilizing these genes that can reliably predict the prognosis of glioma patients. The risk signature showed a positive correlation with T cell exhaustion and increased infiltration of immunosuppressive cells, and a negative correlation with the response to immunotherapy. Moreover, we discovered that SH2D4A, one of the risk hub genes, could stimulate the migration and proliferation of glioma cells. Conclusions: This study identified risk hub genes and established a risk model by analyzing the genomic heterogeneity, stemness, and immune microenvironment of glioma. Our findings will facilitate the diagnosis and prediction of glioma prognosis and may lead to potential treatment strategies for glioma.

26 November 2025 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
FWFeiyun Wang
Feiyun Wang
RGRuilei Guan
Ruilei Guan
GYGuanyu Yang
Guanyu Yang
DZDongya Zhang
Dongya Zhang
ZLZhengkai Li
Zhengkai Li
QCQinjun Chu
Qinjun Chu
Background: Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α -synuclein aggregation. Current treatments do not halt disease progression. Recent research highlights impaired cerebral lymphatic drainage in PD, suggesting a potential therapeutic target. Case presentation: We report a 56-year-old male with advanced PD who underwent deep cervical lymphovenous bypass (DCLB) surgery, a novel intervention designed to enhance lymphatic drainage by anastomosing the deep cervical lymphatic vessel to a vein. The patient had been diagnosed with PD in 2024 after experiencing progressive motor symptoms since 2019, with suboptimal response to conventional pharmacotherapy. Results: At three-month follow-up, significant improvements were observed: Movement Disorder Society–Unified Parkinson’s Disease Rating Scale decreased by 30.4% (from 23 to 16), Non-Motor Symptoms Scale decreased by 71.4% (from 77 to 22), and Parkinson’s Disease Questionnaire-39 decreased by 94.2% (from 52 to 3). Both motor symptoms (rigidity, bradykinesia) and non-motor symptoms (sleep disturbances, orthostatic dizziness) showed improvement. Conclusion: DCLB was technically feasible and was followed by symptomatic improvements in this single patient. The underlying mechanism for this clinical response remains unclear and was not investigated with biomarkers in this report. While these preliminary findings are hypothesis-generating, causality cannot be inferred from an individual case. Further controlled studies incorporating neuroimaging and fluid biomarkers are needed to explore potential mechanisms.

3 June 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
JCJiashu Chen
Jiashu Chen
YZYuchi Zhuang
Yuchi Zhuang
MMMeng Mao
Meng Mao
QCQinjun Chu
Qinjun Chu
ZXZhengyuan Xia
Zhengyuan Xia
YWYan Wang
Yan Wang
Perioperative anxiety is a common psychophysiological stress response experienced by patients before and after surgery, with a global prevalence of approximately 48%. Its occurrence is influenced by multiple factors including age, sex, type of surgery, and psychosocial determinants. The underlying pathophysiological mechanisms are complex, involving multi-system interactions such as autonomic nervous system imbalance, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, dysfunction of limbic system neural circuits, and neuroinflammation. Current assessment strategies are evolving from sole reliance on psychological scales toward multimodal approaches incorporating objective biomarkers including heart rate variability, cortisol, and electroencephalography. Management paradigms have shifted from traditional pharmacological premedication to integrated systems encompassing structured patient education, digital health tools, neuromodulation techniques, and cognitive behavioral therapy. However, significant gaps persist regarding standardized screening protocols, biomarker validation, and targeted intervention pathways for high-risk populations. Future management is likely to require more individualized risk assessment and intervention selection. Biomarker-based risk prediction, artificial intelligence-assisted intervention decision-making, and the deep integration of digital therapeutics such as virtual reality with existing enhanced recovery pathways will be key directions for improving patient outcomes and recovery quality. This structured narrative review summarizes current evidence on perioperative anxiety in adults, focusing on epidemiology, pathophysiological mechanisms, assessment tools, biomarkers, and multimodal management strategies.